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Introduction
IL-12 is a 70 kDa heterodimeric cytokine (p70), comprising 
a 35-kDa light chain (known as p35 or IL-12α) and a 40-kDa 
heavy chain (known as p40 or IL-12β) linked by a disulfide 
bridge. IL-12 was first discovered in 1989 [865725]. p35 
is homologous with other single-chain cytokines, whereas 
p40 is homologous with the extracellular domain of 
members of the hematopoietic cytokine receptor family 
[768923]. Production of p35 is rate-limiting and tightly 
regulated, and requires co-expression of p40 for secretion 
of biologically active IL-12 [699110]. IL-12 is predominantly 
produced by dendritic cells (DCs) and phagocytes 
(monocytes/macrophages and neutrophils) in response to 
microbial stimulation. It has a critical role in promoting the 
differentiation of naive CD4+ T-cells into mature T-helper 
(Th)1 effector cells, and stimulating natural killer (NK)-cells 
and T-cells to produce IFNγ via the IL-12 receptor, which is 
composed of two subunits, IL-12Rβ1 and IL-12Rβ2 [768923]. 
IL-12 overproduction has been correlated with enhanced 
proinflammatory activities and tissue damage typical of 
organ-specific autoimmunity in some animal models 
[263937], [865729], [888303]. Similarly, increased expression 
of IL-12 has been detected in patients with rheumatoid 
arthritis (RA) [865726], Crohn's disease (CD) [865728], 
psoriasis [865729] and multiple sclerosis (MS) [865731], 
compared with non-inflammatory controls. Therefore, IL-12 
has been proposed to play a major role in the etiology of 
these autoimmune and inflammatory diseases.
IL-23, a heterodimeric cytokine composed of a p19 subunit 
and the p40 subunit of IL-12, was discovered in 2000 [865732]. 
p19 has an overall sequence identity of approximately 40% 
with the p35 subunit of IL-12. Similarly to IL-12, the formation 
of biologically active IL-23 requires the synthesis of both 
p19 and p40 subunits within the same cell [699110]. 
IL-23 is also expressed predominantly by activated DCs and 
phagocytic cells [693823]. It binds to a receptor (IL-12R) 
that is formed by IL-12Rβ1 and a unique receptor subunit, 
IL-23R. IL-23 affects memory T-cell and inflammatory 
macrophage function, and stimulates a unique lineage of 
Th cells (named Th-17) to produce IL-17, a critical regulator 
in the establishment and perpetuation of autoimmune 
inflammatory response [693823]. Some studies 
have suggested that IL-23 rather than IL-12 is the 
most influential cytokine in several mouse models 
of autoimmune inflammation [865734], [865735]. 
Overproduction of IL-23 has been detected in patients with 
CD [865736], psoriasis [865737], RA [865738] and MS 
[865739], and is associated with the overproduction 
of proinflammatory cytokines, such as IL-6, TNFα and 
IL-17 [693823]. The IL-23R gene on chromosome 1p31 
has been reported to be significantly associated with CD; 
polymorphisms in the gene confer different susceptibilities 
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to CD [768909]. IL-23 may play an even more important role 
in the etiology of these autoimmune diseases than IL-12.
CD, psoriasis, RA and MS are typical T-cell-mediated 
autoimmune diseases, characterized by an excessive CD4+ 
Th1 response, resulting in enhanced production of IL-1, IL-6 
and TNFα [888304]. Conventional therapy for these diseases 
often consists of corticosteroids or immunosuppressive 
drugs, although there is a subset of patients who are 
unresponsive to these therapies. In addition, the side effects 
of such drugs (eg, infections) remain a concern [888315]. 
TNFα inhibitors (eg, etanercept, infliximab and adalimumab) 
[888304] and IL-6 inhibitors (eg, tocilizumab) [479030] 
have proven to be effective and have been approved for 
the treatment of these conditions; however, they are 
associated with a variety of opportunistic infections, such as 
tuberculosis [479030], [659381], and not all patients respond 
well to the therapies, possibly because of underlying genetic 
differences [888324]. Seeking new treatments, such as the 
blockade of IL-12 and IL-23, may offer alternative or even 
better approaches for the treatment of these diseases.
Therapeutic approaches targeting p40 (eg, anti-IL-12/IL-23 
p40 antibodies) can prevent the binding of IL-12 and IL-23 
to IL-12Rβ1 and thus abrogate their proinflammatory effects 
[753334]. ABT-874, a fully human mAb against the p40 
subunit of IL-12 and IL-23, is currently under development 
by Abbott Laboratories, under license from Cambridge 
Antibody Technology Group plc, for the potential treatment of 
autoimmune diseases, including CD and psoriasis [331466], 
[525630].
Synthesis and SAR 
Antibodies to human IL-12 (including p70 and p40) were 
isolated by screening three separate single-chain variable 
fragment (scFv) phage display libraries; these were 
prepared using variable light (VL) and variable heavy (VH) 
cDNAs derived from human tonsil cells, peripheral blood 
lymphocytes and bone-marrow derived lymphocytes. 
Screening of human VL and VH cDNA libraries identified a 
series of anti-IL-12 antibodies. One of these (referred to as 
Joe 9 or Joe 9 wild-type) had relatively low affinity and a 
dissociation rate constant (Koff) of approximately 0.1 sec
-1, 
and was selected for further development. The affinity 
of Joe 9 was improved by conducting mutagenesis of the 
heavy and light chain complementarity-determining regions 
(CDRs), which produced a panel of VL and VH regions that 
were assorted and further mutated, yielding panels of anti-
human IL-12 antibodies, some of which had increased affinity 
[889923].
One of these antibodies, referred to as Y61, demonstrated 
a significant improvement in binding affinity (Koff of 
approximately 2 × 10-4 s-1). The affinity of Y61 was further 
optimized by individually mutating specific amino-acid 
residues within the heavy and light chain CDRs that occupied 
a preferred selective mutagenesis position, contact position 
and/or a hypermutation position. A Gly to Tyr substitution 
at position 50 of the light chain CDR2 and a Gly to Tyr 
substitution at position 94 of the light chain CDR3 resulted in 
a preferred recombinant neutralizing IgG1 antibody, named 
J-695 [889923] and later ABT-874 [578232]. 
Preclinical development
The in vitro binding of ABT-874 (presumed to be binding 
to recombinant human IL-12, as few details are given) was 
characterized by an association rate constant (Kon value) of 
5 × 105 M-1, a Koff value of 5.1 × 10
-5 sec-1 and a Kd value of 
100 pM. The slow Koff value reportedly resulted in a half-life 
of the antibody/protein complex of approximately 300 min. 
ABT-874 was also reported to bind to the p40 subunit of 
IL-12, and to bind human IL-12 and IL-23 with comparable 
affinities (no values provided) [594620].
The functional activities of ABT-874 were measured in 
vitro [594620], [889923]. ABT-874 inhibited the binding 
of radiolabeled IL-12 to the IL-12R on phytohemagglutinin 
(PHA)-activated lymphoblasts with an IC50 value of 
approximately 11 pM, and inhibited IL-12-stimulated PHA-
activated lymphoblast proliferation with an IC50 value of 
approximately 10 pM. ABT-874 also suppressed human IFNγ 
production from IL-12-stimulated, PHA-activated lymphoblasts 
with an IC50 value of approximately 5 pM. In neutralization 
assays with IL-12 from different species, ABT-874 blocked the 
function of human, rhesus monkey, cynomolgus monkey and 
baboon IL-12 (IC50 values = 5, 10, 10 and 15 pM, respectively); 
it was approximately 70-fold less active against canine 
IL-12 than human IL-12 and did not react with mouse or rat 
IL-12 [594620]. The binding of ABT-874 to immobilized human 
IL-12 was blocked by human IL-12 p70 and p40, but not by 
any other cytokines, such as IL-2, IL-4 and IFNγ [889923].
In early in vivo studies, the effects of ABT-874 and the 
related, but unoptimized, mAb Y61 on IL-12-induced 
responses were examined in cynomolgus monkey [594620], 
[889923]. Y61 (1 or 10 mg/kg) significantly reversed 
IL-12-induced hematological changes (which included 
decreases in white blood cells, platelets, lymphocyte 
count and monocyte count) and increased plasma levels of 
neopterin, a marker of monocyte activation, in response to 
IFNγ [889923]. ABT-874 (0.05, 0.2 or 1.0 mg/kg, either sc or 
iv) prevented leukopenia and thrombocytopenia associated 
with human IL-12 administration, and dose-dependently 
suppressed neopterin production with an ED50 value of 
< 0.05 mg/kg [889923]. Approximately 90% inhibition of 
IL-12-induced neopterin was achieved by a serum ABT-874 
concentration of 1 µg/ml. The two routes of administration 
were reportedly equally effective [594620].
In a mouse model, ABT-874 (16 ng/kg to 50 µg/kg ip, on 
days 0, 2 and 4) dose-dependently inhibited IFNγ production 
induced by injection of a chimeric IL-12 protein (composed of 
murine p35 and human p40 subunits; 5 mg ip, on days 1 to 
4) with an ED50 value of approximately 1 µg/kg [594620]. 
Surrogate antibodies homologous to ABT-874 were tested 
in rodent models because ABT-874 lacks affinity to rodent 
IL-12. C17.15, a rat anti-mouse-IL-12 antibody, which is highly 
similar to ABT-874 based on the biomolecular interaction 
assay, receptor binding assay and PHA blast assay, was 
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tested in murine models of autoimmune diseases [889923]. 
In mice with collagen-induced arthritis, C17.15 (10 mg/kg ip, 
on alternate days from day 1 to 12) significantly delayed the 
onset and inhibited the severity of arthritis compared with 
controls. In a mouse model of experimental trinitrobenzene 
sulfonic acid-induced colitis, single doses of C17.15 
(0.1, 0.25, 0.5 or 0.75 mg iv) decreased IFNγ secretion 
from CD4+ T-cells and IL-12 production from macrophages, 
significantly increased body weight and reversed histological 
indicators of colitis [889923]. In a mouse model of 
experimental autoimmune encephalomyelitis, two surrogate 
anti-IL-12 p40 antibodies (10F6 and C17.8) significantly 
reduced disease severity [594620].
Toxicity
In cynomolgus monkeys, ABT-874 was given safely at doses of 
0.05, 0.2 or 1.0 mg/kg. In independent toxicity studies, doses of 
up to 100 mg/kg were reportedly safe in monkeys [889923].
Metabolism and pharmacokinetics
Few details have been published on the pharmacokinetic 
parameters of ABT-874. In a phase I clinical trial, healthy 
volunteers (n = 64) were administered ABT-874 at doses 
ranging from 0.1 to 5.0 mg/kg (sc or iv). Both the Cmax and 
AUC values increased linearly with increasing doses and the 
terminal phase half-life was approximately 9 days. A dose 
of 1 mg/kg was required to maintain a serum antibody 
concentration of 1 µg/ml [594620], [557257].
Clinical development
Phase I
In a double-blind, crossover, phase I clinical trial, healthy 
male volunteers (n = 64) were administered ascending doses 
of ABT-874 (0.1 to 5.0 mg/kg) or placebo. ABT-874 did not 
increase complement fragment C3a at 15 min post-dosing. 
C-reactive protein and fibrinogen levels were only increased 
in individuals in whom symptoms of concurrent infections 
were observed [889923]. 
Phase II
CD
A randomized, double-blind, multicenter, placebo-controlled, 
phase II clinical trial was conducted in patients (n = 79) with 
moderately active CD, which was defined as a score of 220 to 
450 on the CD activity index (CDAI). Patients received seven 
weekly injections of ABT-874 (1 or 3 mg/kg sc), with either 
a 4-week interval between the first and second injection 
(cohort 1) or with no interruption (cohort 2), or placebo. 
Patients could continue to receive certain medications, such 
as antibiotics, mesalamine, sulfasalazine and prednisone 
(≤ 20 mg/day), but could not receive methotrexate, 
ciclosporin or anti-TNF therapies [578232]. 
In cohort 1, remission (defined as a CDAI score of ≤ 150) 
was achieved in 0, 19 and 12% of patients receiving placebo, 
1 or 3 mg/kg ABT-874, respectively, at 4 weeks after the 
first injection. Remission was achieved in 38, 31 and 44% 
of the respective groups at the time of final injection (9 
weeks) and remission was achieved in 13, 19 and 50% of 
patients at the end of the 18-week follow-up. The clinical 
response (defined as a reduction in the CDAI score of at 
least 100 points) rates for this cohort were also higher in the 
ABT-874-treated groups, but there was no statistical 
significance in the differences in either response or remission 
rates between the treatment and placebo groups [578232]. 
In cohort 2, a clinical response was achieved in 25, 27 and 
75% of patients receiving placebo, 1 or 3 mg/kg ABT-874 at 
the time of final injection (7 weeks), respectively, and was 
achieved in 25, 20 and 69% of patients in the respective 
groups at the end of the 18-week follow up. A remission was 
achieved in 0, 8 and 38% of patients in the respective groups 
at the time of final injection (7 weeks), and was achieved 
in 0, 13 and 38%, respectively, at the end of the 18-week 
follow up. The response rate in the 3-mg/kg group at the 
end of 7 weeks of treatment were significantly higher than 
those in the placebo group (75 versus 25%, respectively, 
p = 0.03). There were no statistically significant differences 
in remission rates and other response rates between groups, 
possibly because of the small sample size [578232].
The difference in treatment effects between cohort 1 and 
cohort 2 may be related to the speed with which maximal 
serum levels of ABT-874 were attained or sustained 
[578232].
In a subgroup study (n = 8), treatment with 
ABT-874 decreased IL-12 (p = 0.03), IFNγ (p = 0.05), TNFα 
(p < 0.01), IL-6 (p = 0.06), IL-23 (p < 0.03) and IL-17 
(p < 0.03) production by mononuclear cells of the colonic 
lamina propria in seven patients who achieved a clinical 
response (one patient who did not have a clinical response 
had an increase in IFNγ secretion and no change in TNFα 
secretion) [578232], [865736]. ABT-874 also inhibited 
mucosal histological abnormalities with the mean modified 
d'Haens score (maximal possible score being 13) decreasing 
from 6.9 before treatment to 3.6 at the end of treatment 
(p = 0.06). The histological improvement was characterized 
by decreased numbers of neutrophils, lymphocytes and 
plasma cells, and reduced epithelial damage, with the 
reappearance of goblet cells [578232]. 
A multicenter, randomized, double-blind, parallel, dose-
ranging, phase IIb clinical trial was ongoing at the time of 
publication. The study aimed to compare the efficacy, safety 
and pharmacokinetics of intravenous infusions of ABT-874 
(200, 400 or 700 mg iv, every 4 weeks) with placebo in 
patients with moderate to severe CD. The planned enrollment 
was 420 patients and study completion was estimated to be 
in December 2010 [883697].
Psoriasis
A double-blind, placebo-controlled, multicenter, randomized, 
phase II clinical trial was designed to evaluate the efficacy 
of ABT-874 in the treatment of patients with moderate to 
severe plaque psoriasis [824563], [883346]. Adult patients 
(n = 180) with psoriasis affecting ≥ 10% body surface area, 
and a psoriasis area and severity index (PASI) score of 
≥ 12 were randomized into six groups (n = 30) to receive 
subcutaneous injections of: (i) ABT-874 (100 mg) every other 
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week for 12 weeks, (ii) a single dose of ABT-874 (200 mg) 
at week 0, (iii) ABT-874 (200 mg) every week for 4 weeks, 
(iv) ABT-874 (200 mg) every other week for 12 weeks, (v) 
ABT-874 (200 mg) every week for 12 weeks, or (vi) 
placebo. The primary endpoint was a 75% improvement 
in PASI (PASI 75) at week 12. The primary endpoint was 
achieved in 93, 63, 90, 93 and 90% of patients in each of the 
ABT-874-treated groups, respectively, compared with only 
3% of those patients receiving placebo (all p < 0.001). More 
than 50% of the patients in the ABT-874 groups (except 
group ii) achieved a 90% improvement in skin clearance, 
compared with none of those receiving placebo [824563], 
[883346]. The percentage improvement in PASI scores 
from baseline increased over time for all ABT-874 groups 
and were significantly greater than placebo at each time 
point (p < 0.001; except for group ii at week 1, which was 
p = 0.02) [883346].
Treatment with ABT-874 was discontinued in patients who 
met the primary endpoint at week 12 and maintenance of 
efficacy was evaluated in the next 36 weeks. At week 24, 
there were substantial percentages of PASI 75 responders in 
the active treatment groups who had maintained responses 
of ≥ 50% in the PASI. Results were 71% (20 of 28 patients), 
68% (13 of 19 patients), 81% (22 of 27 patients), 89% (25 of 
28 patients) and 85% (23 of 27 patients) in the five ABT-874 
dosing groups, respectively [835318]. The efficacy at week 
48 had not been reported at the time of publication.
Other diseases
A multicenter, randomized, double-blind, phase II clinical 
trial in MS was initiated in May 2004. Patients received 
ABT-874 (dosed weekly or on alternate weeks) or placebo, 
for 24 weeks, which was to be followed by a 24-week open-
label extension phase. The primary outcome measure was to 
be the comparison over 24 weeks of cumulative gadolinium-
enhanced (T1 weighted) lesions [541710], [667912]. This 
study has been completed, and ABT-874 reportedly met its 
primary endpoint; however, Abbott has announced that it will 
not be advancing the treatment in this indication [883700] 
for reasons that were unknown at the time of publication.
ABT-874 was midway through a phase II clinical trial in RA 
in January 2002 [435220], [443491]; however, no clinical 
findings relating to RA treatment with ABT-874 have been 
reported.
Phase III
A phase III clinical trial began in patients (n = 1350) with 
moderate to severe chronic plaque psoriasis in December 
2007. Primary endpoints were to be the proportion of 
patients achieving a physician global assessment (PGA) 0/1 
(clear or minimal) response at week 12, a PASI 75 response 
at week 12, or maintaining a PGA response of 0/1 at week 
52. The study was expected to be completed in September 
2009 [862623].
Side effects and contraindications
In the phase I clinical trial with healthy male volunteers 
(n = 64), the most commonly observed adverse events were 
headache and common cold/bronchitis, neither of which 
was categorized as severe. ABT-874 was well tolerated, with 
no individuals withdrawing as a result of adverse events 
[889923].
A double-blind trial in patients with moderate CD 
(n = 79) indicated that ABT-874 (1 or 3 mg/kg sc) was 
well tolerated. The most frequently reported adverse 
event was a local injection site reaction, which was 
significantly more common in the ABT-874 groups (77 to 
88%) than in the placebo group (25%). The majority of these 
reactions were mild and responded to symptomatic 
therapy. The incidence of other adverse events, such as 
nausea, vomiting, urinary tract infection, cough, headache, 
fever and fatigue, was not significantly different among 
the groups. There were no serious infections. In 
this trial, clinically significant laboratory abnormalities 
were observed in 27% of patients in all ABT-874-treated 
groups and in 31% of patients in the placebo group. 
The most frequent abnormalities were hyperuricemia 
(17% in the ABT-874 groups and 13% in the placebo 
group), hypoglycemia (3% in the ABT-874 groups), 
hyperamylasemia (3% in the ABT-874 groups) and 
hyperphosphatemia (3% in the ABT-874 groups). None of 
these abnormalities required withdrawal from the study. 
Antidrug antibodies were detected in three patients who 
received ABT-874 (1 mg/kg) and one was considered drug-
unrelated [578232].
The safety of ABT-874 in the treatment of psoriasis was 
evaluated in a phase II clinical trial. During the treatment 
period (12 weeks), the most common adverse event was 
injection-site reaction, occurring in 16.7% of patients 
in the ABT-874 groups and none in the placebo group 
(p = 0.03). The rate of infection ranged from 23 to 43% 
in the ABT-874 treatment groups and was 23% in the 
placebo group, with the most common infection being 
nasopharyngitis; incidence was 7 to 17% for ABT-874 and 
3% for placebo. There were no statistically significant 
differences for the rate of infections between treatment and 
placebo groups. No serious infections were reported, and no 
deaths occurred [824563], [883346]. 
Patent summary
ABT-874 was first claimed in US-06914128 by Abbott 
(formally BASF AG) and the Genetics Institute LLC 
(part of Wyeth, which collaborated with Cambridge Antibody 
to develop other agents). This patent was granted and has 
an expiry date in March 2020. Also originating from Abbott 
and Wyeth, and a member of the same patent family, 
WO-00056772 discloses human antibodies binding human 
IL-12, methods for their production and their use in IL-12-
related diseases, such as RA, CD and MS. Both cases list 
Cambridge Antibody (now part of AstraZeneca plc) as an 
affiliate.
Subsequent claims are made by Abbott in WO-2007014162, 
which discloses methods for the synthesis of ABT-874, and 
by Wyeth in WO-2007076062, which discloses reduced 
viscosity formulations of ABT-874 and other mAbs.
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Current opinion
As anticipated, blockade of the binding of IL-12/IL-23 to 
their shared receptor IL-12Rβ1 by ABT-874 has resulted 
in significant clinical efficacy in the treatment of CD and 
psoriasis in phase II clinical trials. The drug is well tolerated 
and significantly inhibits the production of proinflammatory 
cytokines, including IL-12, IFNγ, TNFα, IL-23 and IL-17, by 
mononuclear cells. The efficacy and safety of ABT-974 in MS 
and RA has not been reported, even though the clinical trials 
have been completed (the MS trial) or implemented for more 
than 5 years (the RA trial). The reasons for this are unknown.
Results from animal studies have suggested that IL-12 
has a biphasic nature as both a proinflammatory and anti-
inflammatory mediator during the onset and progression of 
chronic inflammation. IL-12-deficient p35-/- mice developed 
more severe collagen-induced arthritis and an increase in 
IL-17-producing CD4+ T-cells, as well as elevated mRNA 
expression of the proinflammatory cytokines TNFα, IL-1β, 
IL-6 and IL-17 in affected tissues [865735]. A low dose of 
IL-12 may act as a proinflammatory mediator able to drive 
inflammatory responses in collagen-induced arthritis, whereas 
a high dose of IL-12 may attenuate arthritic inflammation 
[865741]. In contrast, IL-23 has a consistent proinflammatory 
effect [693823], [865734]. Therefore, the clinical efficacy 
of ABT-874 may predominantly be the result of inhibition of 
IL-23, rather than IL-12. This needs to be confirmed by clinical 
studies.
Furthermore, studies using IL-12 knockout mice have 
suggested that IL-12, through induction of IFNγ, plays a 
key role in the host defense of mice against a variety of 
intracellular bacterial, viral, fungal and parasitic pathogens 
[865729], [768923]. Studies in individuals with genetic 
deficiencies in p40 have demonstrated that these patients 
display a syndrome characterized by predisposition to 
infection by BCG, non-tuberculous mycobacteria and 
Salmonella [768923], [865729]. Vigilance for the occurrence 
of such infections in patients treated with anti-IL-12 p40 
agents is warranted, although no increased susceptibility to 
infections has been reported in ABT-874 trials. Compared 
with IL-12, IL-23 may play a limited role in host defense 
[768931]; therefore, antagonists of IL-23 p19 represent 
viable candidates not only to ameliorate inflammation, but 
also leave the IL-12/IFNγ axis intact, thereby being less likely 
to compromise immunity to these opportunistic pathogens. 
Endogenous IL-12 can resist transplantable tumors in most 
mice and carcinogenesis-induced fibrosarcoma in mouse 
tumor models. IL-12 treatment inhibits the establishment 
of tumors or induces the regression of established tumors 
[768923]. Possible liability to increased incidence of tumors 
should be monitored over the long term in patients treated 
with anti-IL-12 p40 agents, including ABT-874, in future 
clinical studies.
Thus far, several other agents targeting the IL-12/23 pathway 
have been developed. Ustekinumab (CNTO-1275; Centocor 
Inc/Janssen-Cilag Ltd) is another fully human IgG1 antibody 
that has a high affinity for IL-12 p40 and potently inhibits the 
biological activity of IL-12 and IL-23; it appears to be highly 
effective and is well tolerated in the treatment of psoriasis, 
as reported in phase II and III clinical trials [764442]. A 
phase II clinical trial of ustekinumab in the treatment of 
CD has also been initiated. The comparability in clinical 
efficacy and safety between ustekinumab and ABT-874 is 
unknown. Another comparable drug is apilimod (STA-5326; 
Synta Pharmaceuticals Corp), an oral small molecule that 
inhibits IL-12 and IL-23 production through the prevention 
of nuclear translocation of c-Rel. Preliminary clinical data 
have suggested that apilimod is effective and safe in the 
treatment of CD and psoriasis, but seems to have less clinical 
benefit than ABT-874 or ustekinumab for psoriasis treatment 
[753334]. An antibody (SMART anti-IL-12 antibody) that is 
specific for IL-12p70 and not for IL-23 was developed by 
Protein Design Labs, but has been discontinued possibly 
because blockage of IL-12 alone is unlikely to be sufficient to 
achieve efficacy.
There have been no reports about the comparability between 
IL-12/IL-23 inhibitors and other biological antagonists, such as 
TNFα and IL-6 inhibitors, in the treatment of the autoimmune 
diseases. IL-12/IL-23 inhibitors have the potential to be more 
effective as a consequence of their ability to suppress various 
pathologically implicated cytokines (IL-12, IL-23, IL-17, IL-6 
and TNFα), but conversely, are less safe because of their 
abrogation of the protective function of IFNγ. The potential 
success of these approaches remains to be determined in 
future clinical trials. In summary, ABT-874 is well tolerated 
and has significant clinical benefit in the treatment of CD 
and psoriasis. Its efficacy and safety in the treatment of 
these and other autoimmune diseases remain to be proven 
by ongoing phase II and III clinical trials.
Licensing
Abbott Laboratories
In August 1993, Cambridge Antibody and Knoll Pharmaceuticals Ltd (now Abbott) initiated a broad collaboration, giving 
Abbott the right to select up to six target antigens for which Cambridge Antibody would develop human antibody therapeutics. 
Cambridge Antibody would receive fees, milestones and royalties on the successful development of any products from this 
collaboration [525630]. By July 1999, Cambridge Antibody had, in conjunction with BASF Pharma (now Abbott), isolated 
and optimized ABT-874, with Abbott responsible for further development and marketing [331466], [525630]. In October 
2003, Cambridge Antibody received the first payment of royalties from Abbott on sales of a drug (adalimumab) derived from 
the agreement in the 6-month period ended June 30, 2003. Abbott paid royalties at the minimum level described in the 
license agreement, which Cambridge Antibody believed was incorrect. The companies started a formal dispute resolution 
procedure [508894]. In October 2005, Cambridge Antibody and Abbott came to a royalty agreement over adalimumab and 
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cancelled their Court of Appeal hearings. Abbott would pay Cambridge Antibody: US $255 million to be passed on to licensors 
(the Medical Research Council, Scripps Institute and Stratagene Corp) in lieu of their entitlement to royalties from January 
01, 2005, onwards; five annual sales-contingent payments of US $9.375 million from January 2006, of which US $2 million 
would go to the licensors; royalties of 2.688% from 01 January 2005; and royalties of 4.75% on future sales of ABT-874 
[630430].
Development status
Developer Country Status Indication Date Reference
Abbott Laboratories US Phase III Psoriasis 10-DEC-07 862623
Abbott Laboratories UK Phase II Crohn's disease 07-JAN-02 435220
Abbott Laboratories UK Discontinued Multiple sclerosis 31-MAY-07 866408
Cambridge Antibody 
Technology Group plc
UK Discontinued Inflammation 12-JUL-99 331466
Abbott Laboratories UK No development reported Autoimmune disease 01-NOV-03 –
Abbott Laboratories UK No development reported Rheumatoid arthritis 01-NOV-03 –
.
Literature classifications
Chemistry
Study type Result Reference
Synthesis Antibodies against IL-12 were isolated from scFv phage display libraries prepared from human tonsil 
cells, peripheral blood lymphocytes and bone-marrow lymphocytes. The Joe 9 fragment was optimized 
by mutagenesis of the heavy and light chain CDRs and reassortment of the panel of fragments. The Y61 
antibody demonstrated improved binding affinity and was optimized by two amino acid substitutions 
to yield the IgG1 antibody ABT-874.
889923
Biology
Study type Effect studied Model used Result Reference
In vitro Binding 
affinity
ABT-874 binding (presumed to be 
to recombinant human IL-12; few 
details are available).
ABT-874 bound IL-12 with a Kon value of 5 × 10
5 
M-1, a Koff value of 5.1 × 10
-5 s-1 and a Kd value of 
100 pM. The half-life of the antibody/protein 
complex was approximately 300 min. ABT-874 
bound to the p40 subunit of IL-12, and bound 
human IL-12 and IL-23 with comparable affinities.
594620
Ex vivo Activity ABT-874 incubated with  
IL-12-stimulated PHA-activated 
lymphoblasts and IL-12 protein 
from various species (details not 
disclosed).
ABT-874 inhibited lymphoblast proliferation (IC50 
value ~ 10 pM) and suppressed IFNγ production 
(IC50 value ~ 5 pM). ABT-874 blocked the function 
of human, rhesus monkey, cynomolgus monkey 
and baboon IL-12 (IC50 values = 5, 10, 10 and  
15 pM, respectively); it was approximately 70-fold 
less active against canine IL-12 than human IL-12 
and did not react with mouse or rat IL-12.
594620
In vivo Efficacy Cynomolgus monkeys treated 
with ABT-874 (0.05, 0.2 or  
1.0 mg/kg either sc or iv) before 
IL-12 stimulation.
ABT-874 prevented human IL-12-induced 
leukopenia and thrombocytopenia, and dose-
dependently suppressed neopterin production 
(ED50 value < 0.05 mg/kg). A 1 µg/ml serum 
concentration of ABT-874 inhibited approximately 
90% of IL-12-induced neopterin. The two routes 
of administration were comparably effective. 
889923
In vivo Efficacy Mice treated with ABT-874  
(16 ng/kg to 50 µg/kg ip, on days 
0, 2 and 4) and stimulated with 
chimeric IL-12 protein composed 
of murine p35 and human p40 
subunits (5 mg ip, on days 1 to 4).
ABT-874 dose-dependently inhibited IFNγ 
production (ED50 value ~ 1 µg/kg).
594620
In vivo Efficacy A surrogate rat anti-mouse-IL-12 
antibody C17.15 was administered 
to mice in models of collagen-
induced arthritis (six doses of  
10 mg/kg ip on alternative days) 
and experimental trinitrobenzene 
sulfonic acid-induced colitis 
(single iv dose of 0.1, 0.25, 0.5 or 
0.75 mg).
C17.15 significantly delayed the onset and 
inhibited the severity of experimental arthritis. 
Histological indicators of experimental colitis were 
reversed by C17.15 treatment; body weight was 
increased, and IFNγ secretion and IL-12 production 
were decreased.
889923
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Associated patent 
Title Human antibodies that bind human IL-12 and methods for producing.
Assignee BASF AG, Du Fou SL, Genetics Institute Inc
Publication WO-00056772 28-SEP-00
Priority US-1999126603 25-MAR-99
Inventors Salfeld JG, Roguska M, Paskind M, Banerjee S, Tracey DE, 
White M, Kaymakcalan Z, Labkovsky B, Sakorafas P, Friedrich S, Myles 
A, Veldman GM, Venturini A, Warne NW, Widom A, Elvin JG, Duncan AR, 
Derbyshire EJ, Carmen S, Smith S, Holtet TL, Du Fou SL.
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Metabolism
Study type Effect studied Model used Result Reference
In vivo Pharmacokinetics Phase I trial in healthy 
volunteers (n = 64) 
administered ABT-874 
(0.1 to 5.0 mg/kg sc or iv).
Cmax and AUC values increased linearly with 
increasing doses and the terminal phase half-life was 
approximately 9 days. A dose of 1 mg/kg was required 
to maintain a serum antibody concentration of 1 µg/ml.
594620
Clinical
Effect studied Model used Result Reference
Safety A phase I, double-blind, crossover trial 
in healthy male volunteers (n = 64) 
administered ascending doses of  
ABT-874 (0.1 to 5.0 mg/kg) or placebo.
ABT-874 did not increase complement fragment C3a at  
15 min post-dosing. The most common adverse events 
were mild or moderate headache and common cold/
bronchitis. ABT-874 was well tolerated and no individuals 
withdrew from the study as a result of adverse events.
889923
Safety and 
efficacy
A phase II, double-blind trial in patients 
(n = 79) with moderate CD were 
randomly assigned to receive seven 
weekly injections (sc) of ABT-874  
(1 or 3 mg/kg) or placebo, either with a 
4-week interval between the first and 
second injection (cohort 1) or with no 
interruption (cohort 2).
In cohort 1, remission was achieved 4 weeks after the 
first injection, respectively, in 0, 19 and 12% of patients 
receiving placebo, 1 or 3 mg/kg; 38, 31 and 44% of 
patients after 9 weeks dosing, and 13, 19 and 50% of 
patients at the 18-week follow up experienced remission 
in the respective groups. In cohort 2, a remission was 
achieved, respectively, in 0, 8 and 38% of patients from 
placebo, 1 or 3 mg/kg at 7 weeks and 0, 13 and 38% at 18 
weeks, respectively. Only the clinical response rate in the 
3-mg/kg group at 7 weeks in cohort 2 was significantly 
superior to placebo (75 versus 25%, respectively, p = 
0.03). ABT-874 was well tolerated, causing generally mild 
injection-site reactions.
578232
Safety and 
efficacy 
A phase II, double-blind, placebo-
controlled trial in patients (n = 180) with 
moderate-to-severe plaque psoriasis, 
randomized to receive: (i) ABT-874  
(100 mg) every other week for 12 weeks, 
(ii) a single dose of ABT-874 (200 mg) 
dose at week 0, (iii) ABT-874 (200 mg) 
every week for 4 weeks, (iv) ABT-874 
(200 mg) every other week for 12 weeks, 
(v) ABT-874 (200 mg) every week for 12 
weeks, or (vi) placebo.
A PASI 75 improvement was achieved in 93, 63, 90, 93 
and 90% of patients in the respective groups compared 
with 3% of those receiving placebo (all p < 0.001). More 
than 50% of the patients in the ABT-874 groups (except 
group ii) achieved a 90% improvement in skin clearance, 
compared with none of those receiving placebo. The most 
common adverse event was injection-site reaction and 
there were no statistically significant differences in rates 
of infections between treatment and placebo groups.
883346
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